Mc-Val-Cit-PABC-PNP: Practical Guide for Cathepsin-Cleavable ADC Linker Application

What This Product Solves

Researchers developing antibody-drug conjugates (ADCs) for targeted drug delivery require peptide linkers that enable precise, controlled payload release within lysosomes. Mc-Val-Cit-PABC-PNP is a cathepsin B-cleavable ADC peptide linker designed to address this challenge. By incorporating a cathepsin B substrate sequence (Val-Cit) and a self-immolative PABC spacer, this linker ensures that conjugated cytotoxic payloads are released efficiently upon lysosomal cleavage. Its robust design has been utilized in the synthesis of clinically relevant ADCs such as brentuximab vedotin, where selective intracellular activation is essential. The product is formulated for solubility in DMSO and similar organic solvents, supporting workflows where aqueous compatibility is not required. Inappropriate use in diagnostic, therapeutic, or aqueous protocols may lead to suboptimal results or loss of function.

For an in-depth technical overview and workflow context, see the internal article "Mc-Val-Cit-PABC-PNP: ADC Peptide Linker for Targeted Delivery", which details selectivity and use cases for this class of linker. Additional technical guidelines are summarized in "Mc-Val-Cit-PABC-PNP: Technical Guide for ADC Linker Application", with a focus on organic solvent-based workflows.

Protocol Parameters

• Solvent Compatibility: DMSO (≥36.9 mg/mL) | Suitable for organic solvent-based ADC synthesis | Ensures adequate dissolution and homogeneous reaction conditions; not soluble in water or ethanol | product dossier
• Storage Conditions: -20°C (solid form) | Recommended for long-term stability | Minimizes degradation and preserves purity (98%) when stored dry; solution stability is limited | product dossier
• Solution Handling: Prepare immediately before use; avoid long-term storage in solution | Applicable for conjugation workflows | The compound's chemical nature leads to degradation if stored in solution, impacting linker integrity | product dossier

Workflow Setup and QC Checklist

Implementing Mc-Val-Cit-PABC-PNP into antibody-drug conjugate synthesis requires careful attention to workflow parameters to ensure linker integrity and functional payload release:

• Solubilization: Weigh the solid compound under dry conditions and dissolve in anhydrous DMSO at the required working concentration. Confirm complete dissolution visually or by gentle vortexing. Avoid water or ethanol as solvents, as these will not adequately dissolve the linker.
• ADC Conjugation: Conduct all conjugation reactions in organic solvent-compatible protocols (e.g., DMSO-based buffer systems). Monitor reaction pH and temperature, as excessive moisture or heat may accelerate linker hydrolysis.
• Aliquoting and Storage: Prepare small aliquots of the solid linker to minimize repeated freeze-thaw cycles. Store unused solid at -20°C in a desiccator. Discard any remaining solution after use rather than refreezing.
• Quality Control: Confirm the integrity of the linker by analytical HPLC or LC-MS prior to use in critical conjugation steps. Verify the purity (≥98%) as specified.
• Documentation: Record batch numbers, preparation dates, and storage conditions for traceability and reproducibility in ADC research workflows.

Common Failure Modes and Fixes

• Incomplete Dissolution: If undissolved material remains after mixing in DMSO, verify solvent quality and temperature. Use anhydrous, room-temperature DMSO, and gently heat (not exceeding 37°C) if required. Avoid sonication, which can promote degradation.
• Degradation During Storage: Storing the linker in solution, especially at room temperature, leads to hydrolysis and reduced activity. Always prepare fresh solutions immediately before use and discard any unused portion after the experiment.
• Conjugation Inefficiency: Poor conjugation yields may result from improper solvent selection or the presence of water. Ensure all glassware, solvents, and reagents are dry, and confirm the linker is fully solubilized before initiating the coupling reaction.
• Unexpected Payload Release Profile: If premature release or lack of lysosomal activation is observed, review the linker-to-antibody ratio, conjugation conditions, and verify enzyme activity in your workflow. Confirm that cathepsin B is present and active in your lysosomal model.

Scope and Limitations

Mc-Val-Cit-PABC-PNP is optimized for antibody-drug conjugate synthesis protocols requiring a cathepsin B substrate linker and lysosomal cleavage specificity. Its application is limited to workflows compatible with organic solvents, primarily DMSO, and is not suitable for aqueous, diagnostic, or therapeutic use. In vivo workflows requiring water-soluble linkers, or applications involving direct clinical or diagnostic exposure, fall outside the product's defined scope. Researchers should not attempt to formulate or deliver this linker in water or ethanol-based systems, as this will result in poor solubility and functional failure.

Conclusion

Mc-Val-Cit-PABC-PNP provides a validated, high-purity cathepsin cleavable ADC peptide linker for targeted drug delivery research, particularly where lysosomal payload release is a critical parameter. Its chemical design supports selective cytotoxic agent release in antibody-drug conjugate workflows relying on DMSO and related organic solvents. For best results, adhere strictly to recommended storage, handling, and workflow protocols as detailed above. For further technical details and to acquire Mc-Val-Cit-PABC-PNP, consult the APExBIO product page.